Search Results
Your search for ,had matches 18492 pages
Showing 16851 - 16900Multicenter Study Redefines Brain Tumor Diagnosis and Treatment
Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated. The study, a project of The Cancer Genome Atlas, found striking molecular differences between various forms of gliomas by looking at the makeup ...
Latina Patients With Breast Cancer Need More Culturally Relevant, Language-Specific Stress Management Tools
It is estimated that one of every three Latina women will be diagnosed with cancer during her lifetime. Moffitt Cancer Center researchers, along with collaborators at the University of South Florida, recently published a study about the attitudes and cultural perspectives of Latinas undergoing...
Addition of Interferon Alfa-2b to MAP Does Not Meet Event-Free Survival Objective in Osteosarcoma With Good Response to Preoperative MAP
In the phase III EURAMOS-1 trial reported in the Journal of Clinical Oncology, Bielack et al found that the addition of postoperative pegylated interferon alfa-2b (Pegintron, Sylatron) to MAP (methotrexate, doxorubicin, and cisplatin) in patients with osteosarcoma showing good histologic response...
ASCO 2015: IMGN853 Demonstrates Single-Agent Activity for Patients With Platinum-Resistant Ovarian Cancer
In a phase I trial, the investigational agent mirvetuximab soravtansine (IMGN853) was found to be active in patients with platinum-resistant ovarian cancer. ImmunoGen, Inc, announced the first clinical findings of this folate-receptor alpha (FRα)-targeting antibody-drug conjugate at the...
HPV Serum Antibodies May Predict Survival and Disease Progression in Patients With HPV-Positive Oropharyngeal Cancer
A study by Dahlstrom et al investigating the usefulness of serum antibodies to human papillomavirus (HPV)-16 DNA antigens as predictors of survival for patients with oropharyngeal carcinoma has found that E1, NE2, and E6 antibody positivity were all strongly associated with improved overall and...
Denosumab Reduces Clinical Fracture Risk in Postmenopausal Women Receiving Aromatase Inhibitors
In a phase III trial (ABCSG-18) reported in The Lancet, Gnant et al found that adjuvant denosumab (Xgeva) reduced the risk of clinical fracture in women with breast cancer receiving aromatase inhibitor therapy. Study Details In the double-blind study, 3,420 women from Austria and Sweden with...
Low Enrollment in Genomically Matched Clinical Trials After Genomic Testing
In an analysis reported in the Journal of Clinical Oncology, Meric-Bernstam and colleagues at The University of Texas MD Anderson Cancer Center found that a small minority of patients with potentially actionable genes identified in large-scale testing were enrolled onto clinical trials targeting...
Need for Mental Health Services for Parents Who Lose a Child to Cancer
In a study reported in the Journal of Clinical Oncology, Lichtenthal et al found that parents who have lost a child to cancer report wanting and frequently using mental health services, although barriers to seeking care exist and retention in care is suboptimal. Study Details The cross-sectional...
Analysis Shows Advantage for Picture-Based vs Text-Based Warnings on Cigarette Packs
Pictures illustrating the dangers of cigarette smoking were more effective at strengthening people’s intentions to quit smoking than text warnings, a University of North Carolina at Chapel Hill analysis of multiple research studies has found. These findings were published by Noar et al in...
French Trial Shows Addition of Docetaxel and Estramustine to ADT Improves Relapse-Free Survival in High-Risk Localized Prostate Cancer
In a French phase III trial (GETUG 12) reported in The Lancet Oncology, Fizazi et al found that the addition of docetaxel and estramustine (Emcyt) to androgen-deprivation therapy (ADT) improved relapse-free survival among patients with high-risk localized prostate cancer. Study Details In the...
16-Gene Assay Recurrence Score Predicts Recurrence After Surgery for Localized Renal Cell Carcinoma
In a study reported in The Lancet Oncology, Rini et al developed a 16-gene assay and recurrence score that predicted postsurgery outcome in patients with stage I to III clear cell renal cell carcinoma. Development Phase In the development phase, examination of the association between expression...
Livers Donated After Cardiac Death Are Safe to Use in Liver Cancer Patients
In the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have similar beneficial outcomes whether using organs donated by patients after cardiac death or brain death. The study was recently published by Croome et al in the American...
New Molecular Diagnostic Test Predicts Progression of Barrett's Esophagus to Esophageal Cancer
Interpace Diagnostics, a subsidiary of PDI, Inc, announced new data demonstrating the clinical value of BarreGen, a molecular diagnostic test that predicts the risk of progression from Barrett’s esophagus to esophageal cancer approximately 3 to 4 years before the cancer develops. These...
DNMT3A Mutations Predict Poorer Outcome in Younger Adults With AML Irrespective of NPM1 Genotype, but Type of Mutation Matters
In a UK study reported in the Journal of Clinical Oncology, Gale et al found that presence of DNMT3A mutations was associated with poorer prognosis in young adults with cytogenetic intermediate-risk acute myeloid leukemia (AML) irrespective of the presence of NPM1 mutation. Poorer outcome was found ...
Palbociclib Improves Progression-Free Survival in Advanced Hormone Receptor–Positive Breast Cancer
In a phase III PALOMA 3 trial reported at the 2015 ASCO Annual Meeting and published in The New England Journal of Medicine, Turner et al found that the cyclin-dependent kinase 4 and 6 inhibitor palbociclib (Ibrance) significantly improved progression-free survival in women with advanced hormone...
Pooled Analysis Shows Activity of Afatinib Differs in NSCLC According to Uncommon EGFR Mutations
In a pooled analysis of the LUX-Lung 2, 3, and 6 trials reported in The Lancet Oncology, Yang et al found that the activity of afatinib (Gilotrif) differed according to uncommon EGFR mutations in advanced non–small cell lung cancer (NSCLC). Most patients with EGFR-mutant NSCLC have deletion...
Polymorphisms Related to Oxidative Stress Associated With Poorer Cognitive Function After Chemotherapy for Childhood ALL
In a study reported in the Journal of Clinical Oncology, Cole et al found that polymorphisms in genes related to oxidative stress or neuroinflammation were associated with poorer cognitive function in survivors treated for childhood acute lymphoblastic leukemia (ALL). Survivors of childhood ALL...
Addition of Elotuzumab to Lenalidomide-Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In an interim analysis of the phase III ELOQUENT-2 trial reported in The New England Journal of Medicine, Lonial et al found that the addition of the investigational agent elotuzumab to lenalidomide (Revlimid)-dexamethasone significantly increased progression-free survival in patients with relapsed ...
Latest RTOG 0537 Data Indicate Electrical Nerve Stimulation May Provide Relief for Radiation-Induced Dry Mouth
Phase III results of Radiation Therapy Oncology Group (RTOG) 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as the prescription medication pilocarpine, the current standard of care, to treat radiation-induced xerostomia (dry...
Risk Algorithm Using Serial CA-125 Measurements Increases the Number of Screen-Detected Ovarian Cancers
As reported in the Journal of Clinical Oncology by Menon et al, findings in the United Kingdom Collaborative Trial of Ovarian Cancer Screening indicate that the number of screen-detected ovarian cancers is doubled by using the risk of ovarian cancer algorithm (ROCA) with serial CA-125 measurements...
Addition of Necitumumab to First-Line Gemcitabine-Cisplatin Improves Overall Survival in Stage IV Squamous NSCLC
In the phase III SQUIRE trial reported in The Lancet Oncology, Thatcher et al found that the addition of the second-generation epidermal growth factor receptor (EGFR) antibody necitumumab to first-line gemcitabine-cisplatin improved overall survival among patients with stage IV squamous...
Men With Asthma Less Likely to Develop Lethal Prostate Cancer
A recent analysis of a large observational study has revealed that men with a history of asthma are less likely than those without it to develop lethal prostate cancer, researchers at Johns Hopkins reported. These findings were published by Platz et al in the International Journal of Cancer....
ASCO 2015: Patient Misconceptions Persist About Impact of Double Mastectomy on Survival
A University of Michigan survey of women with breast cancer found that nearly half considered having a double mastectomy—but of those who considered it, only 37% knew that the more aggressive procedure does not improve survival for women with breast cancer. Among women who received a double...
ASCO 2015: Study Supports IDH Gene as Prognostic Marker in Anaplastic Astrocytoma
New findings from a phase III clinical trial suggest the IDH1 gene may be a prognostic marker for anaplastic astrocytoma, a rare form of brain cancer. The results of this study were presented on June 2 at the 2015 ASCO Annual Meeting in Chicago (Abstract 2002). Patients in this study who had a...
Bronchial Gene-Expression Classifier Improves Bronchoscopy Performance in Diagnosing Lung Cancer
In a study reported in The New England Journal of Medicine, Silvestri et al of the AEGIS study team found that use of a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy in patients being evaluated for suspected lung cancer. Study Details The study...
Addition of Bevacizumab to Radiotherapy and Temozolomide Does Not Worsen Health-Related Quality of Life in Glioblastoma Patients
In the phase III AVAglio trial, the addition of bevacizumab (Avastin) to radiotherapy and temozolomide improved progression-free survival in patients with newly diagnosed glioblastoma. As reported by Taphoorn et al in the Journal of Clinical Oncology, bevacizumab treatment did not worsen...
ASCO 2015: New Targeted Treatment IMMU-130 Shows Activity in Patients With Metastatic Colon Cancer
Although various drugs have improved outcomes for metastatic colon cancer patients, researchers continually strive to find new agents to improve treatment. Antibody-drug conjugates are a promising option, due to the fact that they can deliver chemotherapy directly into a targeted cell, destroy...
Higher Tumor-Infiltrating Lymphocyte Level Associated With Better Outcomes in HER2-Positive Early Breast Cancer Independent of Neoadjuvant Treatment
In an analysis of the NeoALTTO trial reported in JAMA Oncology, Salgado et al found that a higher level of tumor-infiltrating lymphocytes was associated with improved pathologic compete response rate and event-free survival independent of neoadjuvant treatment received in patients with...
ASCO 2015: Novel Targeted Drug Palbociclib Slows Progression of Hormone Receptor–Positive Breast Cancer
Results from the phase III registration study PALOMA-3 show that adding the investigational targeted agent palbociclib (Ibrance) to the standard hormonal therapy fulvestrant (Faslodex) more than doubled the duration of disease control, delaying disease progression by roughly 5 months in women with...
ASCO 2015: Anastrozole Offers Higher Breast Cancer–Free Interval Rates Than Tamoxifen Following Lumpectomy and Radiation for DCIS
A phase III trial comparing 5 years of tamoxifen vs 5 years of the aromatase inhibitor anastrozole for postmenopausal women treated for ductal carcinoma in situ (DCIS) found 10-year breast cancer–free interval rates were higher in the anastrozole group than in the tamoxifen group (93.5% vs...
ASCO 2015: Entolimod May Be a Promising Treatment Option for Many Solid Tumors
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute, shared results from the first clinical study of the anticancer effects of the novel agent entolimod on May 30 at the 2015 ASCO Annual Meeting in Chicago (Abstract 3063). Their findings confirm ...
ASCO 2015: Economic Costs a Burden for Cancer Survivors
A new study conducted by the American Cancer Society found that the economic burden of cancer extends beyond diagnosis and treatment, with cancer survivors facing thousands of dollars of excess medical expenses every year, as well as excess employment disability and loss of production at work. The...
ASCO 2015: Eribulin Extends Overall Survival for Heavily Pretreated Patients With Advanced Liposarcoma and Leiomyosarcoma
Heavily pretreated patients with intermediate- or high-grade liposarcoma or leiomyosarcoma had a 2-month increase in median overall survival when subsequently treated with eribulin (Halaven) rather than the standard drug dacarbazine. “For a disease where so few treatment options exist, a...
Adjuvant Regimen Produces Good Survival Results in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
In a phase II Intergroup study (SWOG S0809) reported in the Journal of Clinical Oncology, Ben-Josef et al found that adjuvant capecitabine and gemcitabine followed by concurrent radiotherapy and capecitabine produced good survival results in patients with extrahepatic cholangiocarcinoma or...
ASCO 2015: Investigational ALK Inhibitor Demonstrates Promising Overall Response Rates in Patients With Advanced ALK-Positive NSCLC
The oral investigational anaplastic lymphoma kinase (ALK) inhibitor alectinib shrank tumors in almost half of patients with advanced ALK-positive non–small cell lung cancer (NSCLC) whose disease had progressed following crizotinib (Xalkori) treatment. Positive results from two clinical...
ASCO 2015: Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients With Multiple Myeloma
A large, cooperative group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide (Revlimid) delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but...
ASCO 2015: First Effective Adjuvant Chemotherapy for High-Risk, Localized Prostate Cancer
“For the first time, improvement in overall survival was observed with tolerable adjuvant chemotherapy for localized, high-risk prostate cancer,” Howard Sandler, MD, Professor of Radiation Oncology at Cedars-Sinai Medical Center in Los Angeles, announced at a press briefing at the...
ASCO 2015: Tumor Sequencing Study Highlights Benefits of Profiling Healthy Tissue
As the practice of genetically profiling patient tumors for clinical treatment decision-making becomes more commonplace, a recent study from The University of Texas MD Anderson Cancer Center suggests that profiling normal DNA also provides an important opportunity to identify inherited mutations...
ASCO 2015: For Patients With Limited Brain Metastases, Adjuvant Whole-Brain Radiation Therapy Increases Cognitive Decline Without Improving Survival
A federally funded phase III trial found that adding whole-brain radiation therapy to radiosurgery did not significantly extend survival of patients with one to three small metastases of the brain, although it did help to control the growth of brain metastases, as evidenced by imaging studies....
ASCO 2015: Elective Neck Dissection Improves Early Oral Cancer Survival
A randomized phase III study resolves long-standing questions about the optimal timing of neck lymph node surgery for patients with early-stage oral cancer by showing that elective neck dissection both improves survival and lowers recurrence rates compared to therapeutic neck dissection performed...
ASCO 2015: Reduction in Late Mortality Among Childhood Cancer Survivors Linked to Improvements in Cancer Care
Survivors of childhood cancer in recent eras have shown a significant reduction in late mortality, and “for the first time, we have been able to attribute that to fewer deaths from treatment-related causes or fewer deaths from late effects of the primary therapy,” Gregory T....
ASCO 2015: Discussing Child’s Cancer Prognosis Beneficial for Parents
New findings by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center show that informing parents about their child’s cancer prognosis—even when the prognosis is less than favorable—is much more likely to give parents peace of mind and hope, rather...
ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis
Findings from the PERSIST-1 study of patients with myelofibrosis show that the JAK inhibitor pacritinib is significantly more effective than best available therapy, which includes a range of off-label treatments, for easing the symptoms of myelofibrosis. At a landmark analysis at 24 weeks of...
ASCO 2015: First-in-Class Targeted Drug Daratumumab Is Effective as Single Agent in Heavily Treated Multiple Myeloma
“Daratumumab monotherapy produced unprecedented overall responses that deepened over time” in a phase II trial among patients with heavily treated multiple myeloma, study author Saad Zafar Usmani, MD, reported at a press conference at the 2015 ASCO Annual Meeting. Dr. Usmani, a...
ASCO 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia
First results from a randomized phase III study show that the combination of ibrutinib (Imbruvica) and bendamustine (Treanda)/rituximab (Rituxan) improves outcomes for patients with chronic lymphocytic leukemia (CLL) that progressed despite prior therapy. At a median follow-up of 17 months,...
ASCO 2015: Obinutuzumab Doubles Progression-Free Survival in Patients With Relapsed, Indolent Non-Hodgkin Lymphoma
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard bendamustine (Treanda) chemotherapy and then following that with single-agent obinutuzumab maintenance therapy “resulted in a statistically significant, but more importantly, a clinically meaningful increase in...
ASCO 2015: Bevacizumab Combination Boosts Survival in Advanced Stomach and Esophageal Cancers
Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these...
ASCO 2015: Study Clarifies Best Treatments for Non–Clear Cell Kidney Cancers
A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred method of first-line treatment. The phase II ASPEN trial, led by researchers at the Duke Cancer Institute, is the first and largest trial ...
ASCO 2015: Pembrolizumab Produces Clinically Meaningful Response in Patients With Recurrent or Metastatic Head and Neck Cancer
Immunotherapy with pembrolizumab (Keytruda) produced a clinically meaningful overall response rate in a study among 132 patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The overall objective response rate was 24.8%, and 57% of patients experienced some tumor...
ASCO 2015: Nivolumab Extends Survival for Patients With Nonsquamous Non–Small Cell Lung Cancer
Superior overall survival was experienced by patients receiving the anti–PD-1 antibody nivolumab (Opdivo) in a randomized phase III study of patients with nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed after a platinum-based doublet chemotherapy. Study...
